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Abstract (250 words) 
Objectives: Healthcare guidelines recommend psychological interventions for childhood 
unusual experiences that are associated with distress or adverse functional impact (UEDs), 
based on adult, rather than child-specific, evidence. We report the first randomised controlled 
evaluation of the acceptability and potential clinical utility of cognitive behavioural therapy 
for childhood UEDs (CBT-UED). 
Design: Pilot randomised controlled trial. 
Methods: Participants aged 8-14 years were recruited from referrals to community services 
for children with emotional/behavioural problems, and screened for self-reported UEDs. 
Results: Of around 1,000 referrals over 36 months, 304 (30%) were identified to the research 
team, 174 (57%) were successfully contacted, 110 (63%) consented to screening, 96 (87%) 
attended a screening assessment, and 51 (53%) reported UEDs. Forty-nine (96%) consented 
to randomisation to either CBT-UED (9-12 weekly sessions of 40-50 minutes, adjunctive to 
usual care, n=24) or treatment-as-usual/waitlist control (TAU/WL, n=25). Childhood 
internalising emotional symptoms (e.g. feeling ‘nervous’/’scared’/’tearful’/’worried’/’sick’; 
proposed primary outcome), UEDs, depression, anxiety, and childhood psychopathology 
(secondary outcomes) were measured at baseline, at 12-weeks, and, where therapy was 
ongoing but incomplete (<12 sessions) at 12-weeks, at end-of-treatment (EOT). Twenty-two 
CBT-UED participants (92%) attended ≥5 sessions. Forty-four participants (90%) completed 
12-week assessments (CBT-UED, n=21/24, 88%; TAU/WL, n=23/25, 92%). Preliminary 
findings were encouraging for emotional symptoms and UEDs, but otherwise mixed.  
Conclusions: Retention, screening, and consent rates were as anticipated; recruitment took 
longer than planned. Trial procedures were acceptable to young people, their families, and 
clinicians. Therapy exceeded 12 weeks, but was well-received, with no serious adverse 
events attributed to participation. Further evaluation is needed.  
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Practitioner points 
• Around half of 8-14 year olds in child and adolescent mental health services reported 
distressing unusual experiences  
• An age-adapted cognitive behavioural intervention appears feasible, and safe to 
deliver, with the potential to augment standard care 
• This is a pilot study and further evaluation is needed 
• Longer term outcomes should be a focus of future evaluation  
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Text: 4962 words 
INTRODUCTION 
Unusual experiences1 (UEs; perceiving or believing things that others find unreal) are 
commonly self-reported by children in the general population (average prevalence 15%, 
range 5% to 95%; Kelleher et al., 2012). In around 20% of cases (van Os and Reininghaus, 
2016), UEs are persistent, and associated with distress, emotional and behavioural problems 
and functional impairment (UEDs). UEDs have been argued to be increasingly specific 
predictors of progression to an ‘at-risk mental state’ from around fourteen years, indicating 
specialist intervention aiming to prevent transition to clinical psychosis, although there is 
debate about the degree of specificity, and need for a broader scope of treatment (Schmidt et 
al., 2015; Schulze-Lutter et al., 2015; van Os and Guloksuz, 2017). Intervention within 
general Child and Adolescent Mental Health Services (CAMHS) is recommended for under 
fourteens seeking help for UEDs, including cognitive behavioural therapy (CBT) to address 
associated difficulties with mood and functioning (United Kingdom National Institute for 
Health and Care Excellence, UK NICE, 2013; Schmidt et al., 2015). As younger children 
with UEs share biopsychosocial features with older adolescents in clinical high risk services, 
and adults with psychosis (Laurens and Cullen, 2016; Zavos et al., 2014), there is potential 
for very early intervention, targeting vulnerability factors to reduce future at-risk 
presentations (Poulton et al., 2014). However, evidence for interventions to date draws 
primarily on work with adults, rather than exclusively under eighteens. Pilot work shows that 
offering psychological interventions to younger children with UEDs, to reduce current 
distress, functional impairment, and, potentially, future mental health risk, is acceptable to 
children and parents, and may improve current wellbeing (Maddox et al., 2013).  
 
 
Footnote: 1We use the term unusual experiences as young people and parents indicated in consultation prior to 
the study that they prefer this to ‘psychotic’ or ‘psychotic-like’ experiences.   
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Later work has underlined the importance of careful adaptation for children: a recent trial 
showed that adult-oriented CBT for psychosis (CBTp) may be inferior to non-specific 
support for those at the younger extreme of at-risk service intakes (Stain et al., 2016). 
 
In the current study, we set out to pilot a novel intervention designed for young people (8-14 
years) with UEDs (CBT-UED), delivered in addition to usual care, and compared, in a 
randomised controlled design, to treatment as usual (TAU). The aim was to test whether 
CBT-UED was a feasible, safe, and potentially helpful addition to TAU, that could be 
evaluated in UK National Health Service CAMHS.  
 
METHOD  
Participants  
Participants aged 8-14 years were recruited to the Coping with Unusual Experiences Study 
(CUES, ISRCTN 13766770) from referrals to community CAMHS for young people with 
emotional and behavioral problems that did not usually reach criteria for formal psychiatric 
diagnosis. We recruited ‘clinically-referred’, rather than ‘help-seeking’ children, as, at this 
age, help is usually sought by parents or schools. The study comprised a baseline screening 
and assessment phase, with a second phase of participation in the trial offered only to young 
people meeting screening criteria; that is, those reporting a UE with emotional symptoms in 
the borderline or clinical range, assessed by the Strengths and Difficulties Questionnaire 
(SDQ, Goodman, 2001). Service clinicians routinely triaged new referrals: those requiring 
specialist treatment for a severe mental illness, a specific clinical disorder, or a neurological 
condition were referred on, and those requiring urgent care were seen immediately. Non-
urgent, appropriate referrals were placed on a waiting list for further assessment and 
treatment, and sent information about the study. We excluded from screening and baseline 
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assessment only participants who: i) required specialist services (on subsequent assessment); 
ii) had insufficient written or spoken English ability to complete assessments; or iii) were 
likely to move away from the local area over the next six months, and thus not be able to 
complete participation in the trial.  
 
Measures  
Demographic and developmental characteristics  
Age, gender, ethnicity, developmental history (speech/motor delay or current motor problem, 
Laurens et al., 2007), and family history of mental illness were reported by primary 
caregivers. Ethnicity was coded dichotomously (BME: any black or minority ethnic group; 
non-BME: white British or Irish). General intelligence (IQ) was approximated from British 
Picture Vocabulary Scale standardised scores (BPVS II, Dunn, Dunn, Whetton, & Burley, 
1997). 
 
Strengths and Difficulties Questionnaire (SDQ, Goodman, 2001) 
We used a self-report SDQ, suitable for screening 8-17 year olds for internalising and 
externalising emotional and behavioural difficulties characteristic of childhood (Goodman, 
Meltzer and Bailey, 1998; Muris, Meesers and van den Berg, 2003; Goodman, Lamping & 
Ploubidis, 2010). Four subscales, each of five items rated 0 (not true), 1 (somewhat true) or 2 
(certainly true), assess internalising (Emotional Symptoms, Peer Relationship Problems) and 
externalising (Hyperactivity/Inattention, Conduct Problems) problems. Higher scores indicate 
greater difficulty. Subscale scores (0-10) combine to form a Total Difficulties score (0-40), 
assessing general childhood psychopathology. Five items, excluded from the total score, 
assess Prosocial Behaviour. The Emotional Symptoms subscale (SDQ-ESS, proposed 
primary outcome) measures symptoms (such as feeling ‘nervous’, ’scared’, ’tearful’, 
8 
 
’worried’, ’sick’) associated with low mood and anxiety. Borderline or clinical scoring (≥6) 
at baseline was a screening criterion for study inclusion, and objective justification for 
offering therapy. Reliable change (i.e. of greater magnitude than the expected measurement 
error of the instrument, Jacobsen and Truax, 1998) was calculated using the population 
standard deviation (SD) of 2.1 (Goodman, 2001); improvement to a score <6 was taken as 
clinically significant change. General childhood psychopathology (SDQ-Total Difficulties, 
including SDQ-ESS) was a secondary outcome. 
 
Unusual Experiences Questionnaire (UEQ, Laurens et al., 2007; 2012; Ames et al., 2014) 
This nine-item, self-report questionnaire assesses unusual perceptions and ideas, 
incorporating five items adapted from the Diagnostic Interview Schedule for Children (DIS-
C; Costello, Edelbrock, Kalas, Kessler, & Klaric, 1985) with good internal consistency and 
validity (Laurens et al., 2012). Items are endorsed on a three-point Conviction scale: 0 (not 
true); 1 (somewhat true); 2 (certainly true). We used an adapted version (Ames et al., 2014) 
so that endorsed UEs were also rated for Frequency over the past two weeks: 0 (not at all); 1 
(only once); 2 (2-4 times); 3 (5+ times); Distress (‘How much has it upset you?’) and adverse 
functional Impact (‘How much has it made things hard at home or school?’), both rated: 0 
(not at all); 1 (only a little); 2 (quite a lot); 3 (a great deal). Item totals (ratings across 
dimensions of conviction, frequency, distress, and impact: range 0-11), were summed to 
create a total severity score, and, by selecting only those items where distress or impact was 
rated >0, a total UED-severity score. Dimension ratings were summed across items to create 
total conviction (0-18), frequency (0-27), and combined distress/impact (0-54) scores (Ruffell 
et al., 2015). Secondary UE outcomes for this study comprised: the number of UEs endorsed 
as somewhat or certainly true (UE-number, 0-9); the number of UEs endorsed with 
distress/adverse impact >0 (UED-number, 0-9); UE-frequency (total frequency dimension 
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scores, 0-27); UE-D&I (combined distress/impact dimension scores (0-54); and UED-
severity (0-99). Higher scores indicated greater severity. Endorsing any UE as somewhat or 
certainly true (UE-number≥1) was the second screening criterion for trial inclusion. 
 
Short Mood and Feelings Questionnaire (SMFQ; Angold et al., 1995)  
The 13-item SMFQ provided a secondary measure of childhood depression, more detailed and 
specific than the SDQ-ESS. Symptom presence over two weeks is self-rated 0 (not true), 1 
(sometimes true), or 2 (true), with a cut-off of ≥8. Convergent validity, sensitivity and 
specificity are good (Angold et al., 1995).  
 
Spence Children’s Anxiety Scale (SCAS, Spence, 1998) 
The 44-item SCAS provided a secondary, detailed measure of childhood anxiety. Symptoms 
of generalized anxiety, panic/agoraphobia, social phobia, separation anxiety, obsessive 
compulsive disorder, physical injury fears, plus six unscored filler items, are self-rated for 
frequency: 0 (never); 1 (sometimes); 2 (often); or 3 (always). The SCAS is validated in 8-15 
year olds; normative mean score across gender and age ranges is 27.4 (SD 16.5); scores of 40+ 
are considered to be in the clinical range and represent the most anxious 16% of the population 
(Spence, Barrett & Turner, 2003; Essau et al., 2011).  
 
Study design  
Participants were randomly allocated, in a 1:1 ratio, to one of two arms, receiving the CUES 
intervention immediately (CBT-UED) or after 12 weeks (TAU/WL). Randomisation was 
carried out by the Clinical Trials Unit of King’s College London, employing blocks of 
randomly varying size, stratified by gender. Usual CAMHS treatment continued irrespective 
of allocation, without any interference from the research team, and was documented for all 
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participants. We calculated the sample size needed to estimate 95% confidence intervals 
(CIs) with a margin of error (ME) of +/- 10% for three key trial parameters: retention rate 
once recruited (estimated 80%); rate of positive screens (estimated 50%); and rate of consent 
to screening (estimated 50% of those approached). A sample of n=60 eligible participants 
was required to estimate retention rates, indicating a need to screen n=120 (95% CI, ME +/- 
9%), and to approach n=240 (95% CI, ME +/- 6%).  Sample size recommendations for 
estimation of variance range from 24 to 50 participants (Julious, 2005; Sim & Lewis, 2012).   
 
Procedure  
The study was approved by the London-Hampstead Committee of the United Kingdom 
National Research Ethics Service (ref. 11/LO/0023), and conducted in accordance with the 
Declaration of Helsinki (World Medical Association, 2013). Study information packs 
explaining the two parts of the study (baseline assessment/screening, followed by the 
treatment evaluation for young people with UEDs) were mailed to parents, with an age-
adapted young person’s version and assent form. A trained researcher explained the study to 
families who expressed interest in participating, and sought parental consent and child assent. 
Consented participants completed screening (UEs and emotional symptoms), and baseline 
(depression, anxiety and childhood psychopathology) assessments, at their school, home, or 
CAMHS clinic depending on convenience for the family. Children used a bespoke online 
survey (SelectSurvey.NET 2.8.5), with researcher support as needed; parents completed 
paper questionnaires. Young people meeting screening criteria (UE-number ≥1; SDQ-ESS 
≥6) were invited to participate in the randomised controlled trial (RCT). Post-treatment 
measures were completed at 12-weeks, irrespective of therapy completion. After 12-weeks, 
the TAU/WL participants were offered therapy. All participants completing therapy were re-
assessed four weeks after their final therapy session (‘1-month post-therapy’). At the request 
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of participating services, families who agreed to future contact were re-contacted for an 
opportunistic uncontrolled follow-up, one to four years after their baseline assessment (‘1-4 
year follow-up’), at which the SDQ and UEQ were re-administered. The trial was registered 
retrospectively (statutory registration of pilot studies was introduced after study 
commencement) but the design was unchanged from the funding application and registration 
preceded completion of recruitment, data-collection and analysis. The trial protocol is 
available upon request from the authors; the CONSORT checklist is included in Appendix A. 
 
Intervention 
The CBT-UED intervention comprised 9-12 individual sessions, each of 40-50 minutes 
duration, usually delivered weekly. Therapy was adapted from adult CBTp interventions, 
drawing on pre-pilot work and both young person and parent consultation (Maddox et al., 
2013; Browning et al., 2013; Table 1). The intervention was manualised, with sessional plans, 
interactivities, between-session tasks, and co-produced, developmentally appropriate 
handouts. Therapy was delivered by the manual co-creator, KB, an experienced CAMHS 
nurse with postgraduate qualifications in CBT, and CBTp. Supervision was provided by SB, 
the lead author of the manual and CAMHS consultant clinician, trainer and trial therapist. 
Therapy adherence was rated by KB and SB using a sessional activity checklist. Four raters, 
independent of therapy delivery, assessed 16 sessions (of 140 completed with 21 participants, 
11%), using a comprehensive checklist of CBT and CBTp activities. Raters agreed on 88% of 
competence ratings and 90% of presence ratings, with no session rated as not competent 
(Nasseri, 2015).  
 
Table 1 here 
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Statistical analysis  
Analyses were performed using the Statistical Package for the Social Sciences (SPSS, v.22, 
IBM, 2013) and STATA version 14.0 (Statacorp, 2015). Baseline characteristics were 
summarized using descriptive statistics. Acceptability of trial procedures was examined using 
proportions and 95% CIs (consent to screening, target 50%; eligibility, target 50% of those 
screened; retention, target ≥ 80%; we anticipated a recruitment rate of 3 participants/month 
from 28 new referrals). Acceptability of treatment was judged by uptake, sessions attended, 
and retention. Potential helpfulness was judged by the proportion of young people showing 
reliable or clinically significant improvement on the SDQ-ESS in the intervention group 
compared to the control group, with Odds Ratios (ORs) transformed to between group effects 
(d) using the Logit method. ORs were also calculated for other categorical outcomes (meeting 
trial screening criteria; UE-number ≥1/<1; UED-number ≥1/<1).  Emphasis was placed on 
CIs of effect size estimates, rather than hypothesis testing, allowing for exploration of 
imprecision around effect sizes. As therapy was ongoing but incomplete (<12 sessions) for 
most participants at 12-weeks, we created, post-hoc, an end-of-treatment (EOT) outcome, 
using 1-month post-therapy scores for young people who were allocated to, but had not 
completed, therapy at 12-weeks, and the 12-week score for all other young people. 
 
Missing data 
Scores for multi-item measures were classified as missing data if three or more items were 
incomplete, and prorated otherwise. One TAU/WL participant withdrew consent to use their 
data. One TAU/WL and three CBT-UED participants missed the 12-week assessment. We 
analysed proposed primary SDQ-ESS and secondary UE scores under the missing at random 
(MAR) assumption (White, Horton, Carpenter, & Pocock, 2011). Predictors of missingness 
were identified using a series of random intercept logistic regression analyses. We 
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investigated age, gender, ethnicity, IQ, baseline SDQ-ESS, UED-severity, and SDQ-Total, 
allocation, and time of assessment (baseline or 12-weeks). For the 1-4 year follow-up, we 
additionally investigated age at follow-up and length of time from randomisation to follow-
up. None of the variables significantly predicted missing data at 12-weeks or follow-up (z 
scores all < 1.8, p values all > 0.08); therefore, we assume missing completely at random 
(MCAR) and no additional variables were controlled in subsequent analyses.   
 
Treatment effect estimation 
Non-categorical clinical outcomes were analysed on an intention-to-treat basis using a 
random intercept logistic regression analysis, comparing outcomes at 12-weeks and EOT 
between the CBT-UED and TAU/WL conditions, with baseline outcome measures as a 
covariate. The same analyses were repeated for the proposed primary outcome (SDQ-ESS) 
and for each secondary outcome variable (UE-number; UED-number; UE-frequency; UE-
D&I; UED-severity; SDQ-Total; depression; anxiety). Between-group treatment effects (d) 
were also calculated as the difference in mean change between groups, divided by SD, 
adjusted for the degree of association between pre and post scores. To estimate sample size 
for future studies, 95% CIs for treatment effects were recalculated for key outcomes, using 
the upper limit of the 80% CI as a robust estimate of variance. 
 
Additional analyses  
As this was a pilot evaluation of a novel intervention, changes in primary and secondary 
outcomes within each allocation group were also examined for each time point, using 
McNemar tests for categorical variables and, for continuous variables, paired t-tests with 
Cohen’s d calculated as the difference between the pre- and post-treatment means divided by 
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the SD of the difference, adjusted for the correlation between pre- and post-treatment scores. 
Again, 95% CIs for estimation of pre-post effects are reported.  
 
Potential predictors of therapy completion (age, gender, ethnicity, IQ, allocation, and SDQ-
ESS, UED-severity, and SDQ-Total scores, each at baseline and 12-weeks) were examined 
using a series of random intercept logistic regression analyses.  
 
For the 1-4 year follow-up, Pearson correlations were employed to examine the association 
with outcomes of participant age at follow-up and time from randomisation to follow-up, 
calculated with and without adjustment for initial allocation. To assess durability of changes 
following treatment, pre-post effect sizes were estimated for within-participant change from 
baseline to 1-month post-therapy and to 1-4 year follow-up (durability indicated by 
comparable changes), and from 1-month post-therapy to 1-4 year follow-up (durability 
indicated by the absence of deterioration).   
    
RESULTS  
Participant flow 
The CUES project recruited from May 2011 to April 2014; follow-ups were completed by 
January 2016. Participant flow is illustrated in Figure 1. Of around 1,000 expected referrals to 
the service (average 28/month over 36 months), 304 (30%; 95% CI: 27% to 33%) were 
identified to the research team as potential contacts, 174 (57%, 95% CI: 51% to 63%) met 
age criteria and were successfully contacted, and 110 (63%, 95% CI: 59% to 67%) consented 
to participate. Ninety-six completed screening (55% of those contacted, 95% CI: 48% to 62% 
[target: 50%]; 87% of those consenting, 95% CI: 81% to 93%). Of 51 meeting screening 
criteria (53%, 95% CI: 43% to 63% [target: 50%]), all but two (96%; 95% CI: 91% to 100%) 
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agreed to randomisation (24 to CBT-UED; 25 to TAU/WL). Actual recruitment rates were 
slower than estimated, necessitating an extension to recruitment (2.7/month recruitment to 
screening [target: 6/month]; 1.4/month meeting screening criteria [target: 3/month]). Forty-
four participants completed 12-week outcomes (90% (95% CI: 82% to 98%); 21/24 CBT-
UED, 23/25 TAU/WL).  
 
Figure 1 here 
 
Baseline demographic and clinical characteristics  
Young people meeting screening criteria had higher scores on all outcome measures, and 
lower IQ scores than those not meeting screening criteria, with mean SDQ-Total, anxiety and 
depression scores in the clinical range (Table 2). Screening positive was not associated with 
age, ethnic background, family/parental history of mental ill-health, or history of 
developmental problems. Young people not meeting screening criteria were more likely to be 
male. Amongst trial participants, SDQ-Total (r=0.4, p=0.008, n=48) and depression (r=0.4, 
p=0.01, n=46) scores were higher in older children. Girls, compared to boys, reported more 
depression (r=0.4, p=0.02, n=46). Lower IQ was moderately associated with higher SDQ-
ESS, UE-frequency, UE-D&I and anxiety scores (r values 0.3 to 0.5, p values < 0.05). All 
other r values were < 0.3, p>0.05.  
Table 2 here 
Adverse events 
We classified as a potential adverse event any deterioration in the young person’s mental 
health or welfare, that was noted by the young person, family/responsible adult, clinical team 
or study team. Any such event judged by any of these parties as related to study participation 
was considered to be an adverse event, and was rated for severity according to the degree of 
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adverse impact upon the young person. Three potential adverse events were identified, all by 
the study team. Two occurred in the TAU/WL group: a non-fatal overdose, and an identified 
social care need, resulting in withdrawal of consent. One occurred in the CBT-UED group: 
readmission to psychiatric hospital following relapse of a pre-existing, relapsing mental 
health condition. No event was considered by the young person, family, treating team, or 
study team to represent a change in presentation arising because of study participation 
(although the identification of the social care need occurred because of participation, the need 
itself did not). In each case, the study team was closely involved in facilitating appropriate 
care.   
 
Therapy completion at 12-weeks 
Of the 21 CBT-UED participants completing a 12-week assessment, four (19%, 95% CI: 
10% to 28%) elected to discontinue therapy early after 5-7 sessions. One more attended only 
five sessions over 12 weeks, and was referred by the treating team to a specialist service after 
the 12-week assessment. The remaining 16 had only completed just over half of their therapy 
sessions by 12-weeks (mean 7.1, SD 2.0; range 4-11 sessions); 60% (range 30% to 90%) of 
the total received by therapy completion (mean 11.9, SD 1.4, range 10-14 sessions). Of the 
three participants not completing a 12-week assessment, one was lost to follow-up before 
starting therapy, one received two sessions before being admitted to hospital and withdrawing 
from the study, and one received six sessions, before being transferred to a specialist service 
and subsequently lost to follow-up.  
 
Therapy uptake after waitlist control 
Of the 23 TAU/WL participants offered therapy after completing the 12-week assessment, 19 
took up the offer and four declined. Of those taking up the offer, 17/19 engaged in a full 
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course of therapy (mean 11.2, SD 1.7, range 8-14 sessions); one started, but was referred to 
another service after seven sessions and was then lost to follow-up; and one attended one 
session only and then dropped out.  
 
Predictors of therapy completion 
Age, gender, ethnicity, IQ, allocation, and SDQ-ESS, UED-severity, and SDQ-Total scores at 
baseline and at 12-weeks were investigated as potential predictors of therapy non-completion 
using a series of random intercept logistic regression analyses. Only SDQ-Total at baseline 
was a significant predictor (Coefficient = 0.2, p=0.02, 95% CI: 0.03 to 0.4, otherwise z scores 
all < 1.1 p values all > 0.3). Post-hoc examination revealed significant subscale differences 
only for Conduct Problems (non-completers mean 4.8, SD 2.3, n=15; completers mean 3.0, 
SD 1.9, n=33; t=2.8, df=46, p=0.007; else, t values < 1.7, p values > 0.1).  
 
Usual care 
Usual care was not documented for the five young people who withdrew consent or were lost 
to follow-up; no data was available for one further TAU/WL participant. For the remaining 
participants (n=21 CBT-UED, n=22 TAU/WL) usual care ranged from no contact (n=8 CBT-
UED, n=9 TAU/WL), through one-off assessment/review without intervention (n=3 CBT-
UED; n=3 TAU/WL), to regular meetings with specialist CAMHS practitioners for support 
tailored to referral problems (n=10 CBT-UED; n=10 TAU/WL). 
 
Does the CBT-UED therapy show potential to improve outcomes compared to usual care? 
The proportion of participants showing reliable change (exceeding expected measurement 
error, Jacobsen and Truax, 1998) and clinically significant change (to a non-clinical score, 
<6) on the SDQ-ESS at 12-weeks and EOT was compared between the CBT-UED group and 
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the TAU/WL group, with ORs transformed to d values using the Logit method. No 
participant showed reliable deterioration. A non-significantly higher proportion of the CBT-
UED group showed reliable improvement (29% CBT-UED; 13% TAU/WL, d(Logit)=0.6, 
95% confidence interval [CI]: -0.02 to 1.2) and clinically significant improvement (from 
above to below the borderline/clinical threshold; 52% CBT-UED; 39% TAU/WL, 
d(Logit)=0.3, 95% CI: -0.3 to 0.9). Allocation groups did not differ significantly on any 
categorical outcome at either 12-weeks or EOT (χ2 values < 1.0 (df=1), p values > 0.5), ORs 
are shown in Table 3. 
 
Continuous outcomes were analysed on an intention-to-treat basis using a series of random 
intercept logistic regression analyses, comparing each outcome firstly at 12-weeks, then at 
EOT, between the CBT-UED and TAU/WL conditions, with baseline score as a covariate. 
Treatment effects (lower score, better outcome) were very small at 12-weeks for the proposed 
primary SDQ-ESS outcome (Coeff. = -0.1, p=0.9, 95% CI: -1.5 to 1.3), and for all secondary 
UE and other outcomes (z scores all < 1.0, p values all > 0.3). At EOT, treatment effects were 
larger: no significant differences were found for SDQ-ESS (Coeff.=-0.4, p=0.6, 95% CI: -1.7 
to 0.9), but there were group differences on the secondary UE measures at EOT, reaching 
statistical significance for UED-severity (Coeff.=-6.8, p=0.04, 95% CI: -13.3 to -0.2), with a 
trend for UED-number (Coeff. -1.0, p=0.07, 95% CI: -2.2 to 0.07) and UE-D&I (Coeff.=-2.6, 
p=0.07, 95% CI: -5.4 to 0.3; otherwise z scores all < 1.3, p values all > 0.2). Group means 
and between group treatment effects (d) are shown in Table 4.  
 
 
Within group, pre-post changes are also shown in Tables 3 and 4, showing no deterioration in 
either group, and overall small pre-post changes within the TAU/WL group (on SDQ-ESS, 
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two UE measures, and SDQ-Total [t values >2.0, p<0.05], and all categorical outcomes, but 
not UE-frequency, UE-number or UED-number, anxiety or depression [t values < 0.2, p > 
0.05]), and larger pre-post changes within the CBT-UED group, particularly at EOT 
(significant t values > 2.5, p values < 0.05; else t values < 2.5, p values > 0.05), except on 
depression, which did not change (t value < 1.0, p value > 0.4). 
 
Tables 3 and 4 here 
 
Do changes persist? 
Young people (n=19) completed 1-4 year follow-up assessments at a mean of 2.5 years (SD 
0.9, range 1.3-3.8) after randomization. Longer time to follow-up was associated with fewer 
UEs (r=-0.6, p=0.01) and fewer UEDs (r=-0.6, p=0.01), irrespective of controlling for initial 
allocation (otherwise r values ranged from 0.1 to -0.3, p values > 0.1). Mean age at follow-up 
was 14.1 years (SD 2.3, range 10.2 to 18.7). Age was unrelated to any outcome score, 
irrespective of initial allocation (r values ≤ 0.3, p values > 0.1). Effect size estimates 
comparing scores from baseline to 1-month post-therapy to 1-4 year follow-up, showed small 
deteriorations from the 1-month post-therapy assessment, and persisting improvement 
compared to baseline. For categorical outcomes, by 1-4 year follow-up, although UE/UED 
rates had increased, associated SDQ-ESS scores were not in the clinical range (Table 5).  
 
Table 5 here 
 
Variance estimates for future power analyses 
Treatment effects and 95% CIs were recalculated for the SDQ-ESS categorical outcomes 
(reliable improvement and clinically significant improvement) using the upper limit of the 
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80% CI for the standard error of ORs, transformed to d values using the Logit method, and 
for the SDQ-ESS and UED-severity baseline and EOT mean scores, using the bootstrapped 
upper 80% CI limit for the standard deviation.  Treatment effects ranged from d=0.2 to 1.3 
for SDQ-ESS reliable improvement; from d=0.3 to 0.8 for SDQ-ESS clinically significant 
improvement; from d=-0.3 to 0.9 for SDQ-ESS mean score; and from d=0.1 to 1.1 for UED-
severity mean score. These estimates suggest sample sizes from n=176 to in excess of 500 
participants to reliably (with 95% power, α =0.05) evaluate between-group change in SDQ-
ESS, and of n=110 to evaluate change in UED-severity. 
 
DISCUSSION 
We evaluated whether our novel CBT-UED intervention, adapted specially for children, was 
feasible, safe, and a potentially helpful addition to usual community CAMHS care. Following 
treatment recommendations, clinical distress (emotional symptoms) was the proposed 
primary outcome. We also measured change in unusual experiences, employing a range of 
indices to determine the most useful measurement for clinical purposes and potential future 
evaluation.  
 
The study was well-received by services, parents and young people. Screening and 
assessment procedures were developmentally appropriate, with good completion in our 
frontline setting. However, assessors needed skills in engagement, and in managing the 
challenge of balancing interactivity/play with task-focused activity. The two-stage design was 
acceptable to participants and their families. The randomisation procedure was 
unproblematic. The CBT-UED intervention was feasible to implement and positively 
received across the board. No adverse events were causally attributed to the therapy or 
assessments. Retention at 12-weeks was good. Over half of participants and families were 
uncontactable for the opportunistic 1-4 year follow-up, possibly reflecting our mobile inner-
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city population. Higher levels of childhood psychopathology, and potentially particularly 
Conduct Problems, were associated with therapy non-completion. Further investigation of 
this is needed: alternative approaches may better suit externalising problems.  
 
Screening suggested that around half of CAMHS referrals have a UE with clinical/borderline 
distress on the SDQ-ESS and could be offered intervention. However, as treatment guidance 
specifies self-reported distress, without clinical criteria, rates may in practice be higher: all 
but one trial participant self-reported distress/impact on the UEQ but 19 young people (17% 
of those screened) reported a UED with SDQ-ESS<6, and were excluded. Selection and 
screening methods may therefore require further investigation to ensure the target population 
is accessed. While the proportion of young people and their families agreeing to screening 
and meeting eligibility criteria was within the target range, the recruitment rate was less than 
half of that predicted, with only a third of referrals put forward to the research team, and only 
half of these contactable. Clinician feedback indicated that, rather than asking all referrals 
about the research, and two thirds having refused contact, they were inadvertently pre-
selecting potentially suitable participants to ask. Routine screening in services may 
circumvent this difficulty, and facilitate investigation of barriers to access.   
 
Therapy was well-delivered, as expected from expert clinicians, but the time needed to 
complete therapy exceeded 12 weeks in nearly every case, and one or two extra sessions (14 
sessions in total) were required for several cases to cover the manualised therapy content. The 
additional input appeared to be useful as outcomes improved slightly between 12-weeks and 
EOT, and may reflect the greater complexity of difficulties in this CAMHS setting compared 
to a general population case series. A longer course of therapy, and an additional month to 
complete therapy, would improve future studies in clinical contexts.  
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The range of estimated treatment effects generally slightly favoured the CBT-UED group, for 
all outcomes except depression and SDQ-Total, and particularly for UE outcomes. There was 
no suggestion that the CBT-UED intervention caused harm, and some positive change with 
TAU/WL. Between group SDQ-ESS differences were smaller than anticipated (d=0.3 to 0.6), 
indicating a substantially larger sample size for a future, similar analysis with adequate power 
to detect between-group differences. UED between group differences were larger, but 
baseline scores differed markedly, despite random allocation, with unknown impact on the 
likelihood and magnitude of change. Findings suggest that CBT-UED may have most 
potential to augment usual CAMHS care by improving UE specific outcomes, rather than 
general psychopathology. Of the UE outcomes, UED-severity changed most consistently, 
and, pending replication, may be an appropriate primary outcome in future studies, 
particularly given its role in influencing future trajectories (Lin et al., 2011). In their 
feedback, young people particularly noted the helpfulness of normalising information about 
coping with UEDs, and suggested that this could usefully be provided from an early age in 
schools, as they wished they had understood their own experiences sooner. 
 
The gains made during any treatment were somewhat durable: only a third of participants still 
met screening criteria at the 1-month post-therapy and 1-4 year follow-ups, with small, non-
significant between group differences at EOT favouring CBT-UED (43% vs. 52%). While 
UEs and UEDs had partially returned by follow-up, reductions in severity and clinical 
distress persisted, potentially reflecting more adaptive ways of responding.  
 
Limitations 
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Several issues should be considered in interpreting findings. The study was a pilot, not 
powered to detect treatment effects, and multiple comparisons were conducted without 
correction. We recruited from a single inner-city UK NHS Trust: findings may be context-
specific. Longer term follow-up assessments were uncontrolled, so cannot inform estimates 
of treatment effects, and all assessments were conducted unblinded, potentially inflating 
effects. Only half of participants could be contacted for the opportunistic 1-4 year follow-up, 
potentially biasing the sample, although attendance was not associated with baseline 
demographic or clinical variables. Alternative follow-up methods, that do not require 
contacting families (e.g. primary care records), could mitigate bias in future studies, with 
provision made to obtain the young person’s ongoing consent (in addition to their original 
assent to parental consent) once they reach 16 years.  
 
Conclusions 
Around half of children presenting to CAMHS with emotional and behavioural difficulties 
may also have a UED warranting an offer of intervention. Our findings indicate that while 
routine care has a small impact in improving UEDs, a novel therapy specifically targeting 
these experiences in childhood was feasible and safe to deliver, and may augment standard 
care. Further evaluation is required. Key issues to consider in future research are the selection 
criteria for participants; the choice of primary outcome and consequent sample size 
implications; the time frame to deliver therapy; and the logistics of following up young 
people living in an inner city setting over a longer time period.   
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Table 1: Intervention content overview by session   
Session number Content 
1. Engagement & 
Assessment 
Rapport, overview, giving folders/pens and paper. Start assessment. 
Benefits of exercise, diet and sleep. 
2. Assessment & 
Goal Setting 
Rapport; problems & goals; Discussion of PLE’s, anxiety & beliefs.  
Introduce a psychological model - why me, why now, why still, what 
helps?  
3. Psychoeducation  What is anxiety/worry/anger? Anxious or worrying feelings are horrid 
but can’t hurt us. Personal triggers, CBT model 
4. Coping strategies  Activity scheduling; distraction; relaxation training: there are things I 
can do myself to manage my worry. Cognitive coping strategies. 
5. Problem Solving  Traffic lights system (stop, think then do). Looking back (reviewing 
how it went) can help me to leap forward. General and personalised 
examples. 
6. Top Brain 
Training  
Understanding PLEs, normalising & psychoeducation; coping 
strategies; role of cognitive biases 
7. Test it out  Behavioural experiments 
8. Set-backs Review model; normalising blips – everyone has bad days; identify 
future difficult situations/times - what signs to look out for; strategies. 
9. Ending Review learning points and ending certificate 
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Figure 1: CONSORT diagram illustrating participant flow through the trial 
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Table 2. Demographic and clinical characteristics of participants at baseline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key: TAU/WL: Treatment as usual/waitlist control group; CBT-UED: Cognitive behavioural therapy for unusual 
experiences with distress intervention group; SD: standard deviation; df: degrees of freedom; IQ: Intelligence Quotient; 
BPVS = British Picture Vocabulary Scale (Dunn et al., 1997). SDQ: Strengths and Difficulties Questionnaire (Goodman, 
2001); ESS: Emotional Symptoms Scale; UE = unusual experience; UE-D&I: Distress and adverse impact associated with 
UE; UED = unusual experience with distress or adverse impact; BME: Black or minority ethnic: MI: Self-reported mental 
illness history;  1n=additional TAU participant (n=25, TAU; 49 trial); 2n=56; 3n=51; 4n=53; 5n=22; 6n=46; 7n=52; 8n=18; 
9n=17; 10n=35; 11n=38; *p<0.05; **p<0.01; ***p<0.001 
 
 
Variable 
TAU/WL 
n = 241 
CBT-UED 
n = 24 
Trial 
total 
n = 481 
Non-trial 
total 
n=61 
Test (trial cf. 
non-trial) 
 
 Mean (SD) t, p 
Age (years) 11.8 (2.0)1 11.5 (2.2) 11.7 (2.1)1 11.6 (1.9) t(108)=0.2, NS 
IQ (BPVS) 84.7 (13.4) 89.4 (19.1) 87.0 (16.5) 93.8 (14.4)2 t(102)=-2.2* 
SDQ-ESS 7.0 (1.0) 7.6 (1.3) 7.3 (1.2) 3.4 (2.0)3 t(82.4)=12.0*** 
UE-frequency 6.7 (3.7) 9.5 (5.9) 8.1 (5.1) 2.8 (4.1)4 t(99)=5.8*** 
UE-D&I 8.2 (5.7) 13.6 (9.5) 10.9 (8.2) 1.4 (2.8)4 t(56.6)=7.6*** 
UED-number 3.0 (1.5) 4.5 (2.4) 3.8 (2.1) 0.8 (1.4)4 t(78.5)=8.2*** 
UE-number 3.8 (2.0) 5.0 (2.2) 4.4 (2.2) 2.0 (2.3)4 t(99)=8.4*** 
UED-severity 18.2 (10.6) 29.4 (18.6) 23.8 (16.0) 3.9 (7.2)4 t(63.7)=7.9*** 
Depression 11.7 (5.6) 12.4 (6.6)5 12.0 (6.0)6 5.3 (4.6)7 t(83.9)=6.1*** 
Anxiety  44.3 (17.3) 47.5 (18.0) 45.9 (17.5) 26.1 (14.1)4 t(99)=6.3*** 
SDQ-Total  20.6 (3.6) 20.9 (6.2) 20.7 (5.0) 12.8 (5.7)3 t(97)=7.4*** 
 % (n) χ2, p 
Gender  
(F:M) 
52%:48% 
(13:12)1 
54%:46% 
(13:11) 
53%:47% 
(26:23)1 
26%:74% 
(16:45) 
χ2(1)=8.3** 
Ethnicity 
BME/non-BME 
42%:58% 
(10:14) 
50%:50% 
(12:12) 
46%:54% 
(22:26) 
53%:47% 
(31/27) 
χ2(1)=0.6, NS 
SDQ-ESS 
Clinical range 
100% (24) 100% (24) 100% (48) 14% (7)3 χ2(1)=74.5*** 
UE 
Present 
100% (24) 100% (24) 100% (48) 64% (34)4 χ2(1)=21.2*** 
UED 
Present 
100% (24) 96% (23) 98% (47) 36% (19)4 χ2(1)42.8*** 
Family/ 
Parental MI 
92%/44% 
(23/11)1 
54%/42% 
(13/10) 
73%/43% 
(36/21)1 
56%/41% 
(34/25) 
χ2(2)=4.0, NS/ 
χ2(2)=0.05, NS 
Speech/motor 
difficulty 
39% (7)8 35% (6)9 37% (13)10 18% (7)11 χ2(1)=3.1, NS 
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Table 3: Variability of change in proposed primary and secondary outcomes within and between participant groups. 
 
  TAU/WL group (n=23) CBT-UED group (n=21) 12-week 
between 
groups ES 
(95% CI) 
EOT  
between 
groups ES 
(95% CI) 
P
ri
m
a
ry
 Assessment: 
Baseline 
Mean (SD) 
12-week 
Mean (SD) 
Pre-post ES 
(95% CI) 
Baseline 
Mean (SD) 
12-week 
Mean (SD) 
Pre-post ES 
(95% CI) 
EOT 
Mean (SD) 
Pre-post ES 
(95% CI) 
SDQ-ESS 7.0 (1.0) 5.8 (2.0) 
0.5* 
(-0.1 to 1.1) 
7.6 (1.2) 5.9 (2.8) 
0.6** 
(0.1 to 1.2) 
5.6 (2.3) 
0.9** 
(0.3 to 1.5) 
0.2 
(-0.4 to 0.8) 
0.3 
(-0.3 to 0.9) 
S
ec
o
n
d
a
ry
 U
E
 
UE-
frequency 
6.8 (3.8) 5.3 (4.9) 
0.4 
(0.1 to 0.7) 
9.0 (6.2) 6.6 (6.0) 
0.4 
(-0.0 to 0.8) 
5.2 (5.7) 
0.7** 
(0.3 to 1.2) 
0.2 
(-0.4 to 0.8) 
0.5 
(-0.1 to 1.1) 
UE-D&I 8.2 (5.8) 5.6 (5.8) 
0.5* 
(0.1 to 0.9) 
12.4 (8.7) 7.0 (7.1) 
0.6* 
(0.1 to 1.1) 
4.9 (5.5) 
1.1*** 
(0.6 to 1.6) 
0.4 
(-0.2 to 1.2) 
0.8* 
(0.2 to 1.4) 
UED-
number 
3.0 (1.5) 2.3 (2.0) 
0.4 
(0.0 to 0.8) 
4.4 (2.5) 2.7 (2.3) 
0.6** 
(0.1 to 1.1) 
1.9 (2.1) 
1.0*** 
(0.4 to 1.6) 
0.5 
(-0.1 to 1.1) 
0.8** 
(0.2 to 1.4) 
UE-number 3.8 (2.0) 3.1 (2.2) 
0.4 
(0.0 to 0.8) 
4.9 (2.2) 3.5 (2.6) 
0.6* 
(0.1 to 1.1) 
2.8 (2.5) 
0.8** 
(0.3 to 1.3) 
0.3 
(-0.3 to 0.9) 
0.6* 
(0 to 1.2) 
UED-
severity 
18.2 (10.8) 13.1 (13.3) 
0.5* 
(0.1 to 0.9) 
27.3 (18.1) 15.9 (15.6) 
0.7** 
(0.2 to 1.2) 
11.2 (13.6) 
1.1*** 
(0.6 to 1.6) 
0.5 
(-0.1 to 1.1) 
0.9** 
(0.3 to 1.5) 
S
ec
o
n
d
a
ry
 m
o
o
d
 /
 
p
sy
ch
o
p
a
th
o
lo
g
y 
 
Depression1 11.7 (5.9) 10.8 (6.0) 
0.2 
(-0.2 to 0.6) 
11.5 (6.2) 10.3 (6.6) 
0.2 
(-0.3 to 0.7) 
10.8 (7.1) 
0.1 
(-0.4 to 0.6) 
0.05 
(-0.6 to 0.7) 
-0.03 
(-0.7 to 0.6) 
Anxiety2 43.4 (17.5) 38.7 (18.7) 
0.3 
(-0.0 to 0.6) 
47.0 (17.4) 38.8 (19.1) 
0.4 
(-0.1 to 0.9) 
35.0 (20.2) 
0.7* 
(0.3 to 1.2) 
0.2 
(-0.4 to 0.8) 
0.5 
(-0.1 to 1.1) 
SDQ-Total 20.8 (3.5) 17.4 (6.0) 
0.6* 
(0.1 to 1.1) 
20.0 (6.3) 18.1 (7.4) 
0.3 
(-0.2 to 0.8) 
17.6 (6.2) 
0.4* 
(-0.0 to 0.8) 
-0.2 
(-0.8 to 0.4) 
-0.2 
(-0.8 to 0.4) 
Key: TAU/WL: Treatment as usual/waitlist control group; CBT-UED: Cognitive behavioural therapy for unusual experiences with distress intervention group; SD: 
standard deviation; SDQ: Strengths and Difficulties Questionnaire (Goodman, 2001); ESS: Emotional Symptoms Scale; UE = unusual experience; UE-D&I: Distress and 
adverse impact associated with UE; UED = unusual experience with distress or adverse impact; 1n=22, TAU/WL; n=20, CBT-UED); 2n=22, TAU/WL; n=21, CBT-UED; 
ES: effect size, Cohen’s d, derived from pre-post or between group change mean differences over the common SD; *p<0.05; **p<0.01; ***p<0.001 – significance levels 
derived from within group paired t-test of pre-post scores or between group independent samples t-test of change scores 
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Table 4: Variability of change in clinical status outcomes within and between participant groups. 
 
Key: TAU/WL: Treatment as usual/waitlist control group; CBT-UED: Cognitive behavioural therapy for unusual experiences with distress intervention group; SCREEN+ve: 
scoring in the clinical range (SDQ-E ≥6; UE-number ≥1); SDQ: Strengths and Difficulties Questionnaire (Goodman, 2001); ESS: Emotional Symptoms Scale; UE = unusual 
experience; UED = unusual experience with distress or adverse impact; OR: Odds Ratio; CI: confidence interval. p-values from McNemar Tests.  
 
 TAU/WL group (n=23) CBT-UED group (n=21) 12-week 
between  
groups OR 
(95% CI) 
EOT  
between 
groups OR 
(95% CI) 
Assessment: Baseline 12-week  Baseline 12-week  
EOT  
 % (n) 
(95% CI) 
p 
% (n) 
(95% CI) 
p 
 
p 
  
SDQ-ESS 
Reliable 
change 
- 
13% (3) 
(6% to 20%) 
- - 
29% (6) 
(19% to 39%) 
- 
29% (6) 
(19% to 39%) 
- 
2.7 
(0.6 to 12.4) 
2.7 
(0.6 to 12.4) 
SDQ-ESS 
Clinical 
range 
100% (23) 
 
61% (14) 
(51% to 71%) 
0.004 
 
100% (21) 
 
48% (10) 
(37% to 59%) 
0.001 
 
48% (10) 
(37% to 59%) 
0.001 
 
1.7  
(0.5 to 5.7)  
1.7  
(0.5 to 5.7) 
SCREEN 
+ve 
100% (23) 
 
52% (12) 
(42% to 62%) 
0.001 
 
100% (21) 
 
48% (10) 
(37% to 59%) 
0.001 
 
43% (9) 
(32% to 54%) 
<0.001 
 
1.2  
(0.4 to 3.9) 
1.4  
(0.4 to 4.8) 
UE 
Present 
100% (23) 
 
78% (18) 
(69% to 87%) 
 
0.06 
 
100% (21) 
 
81% (17) 
(72% to 90%) 
0.1 
 
76% (16) 
(67% to 85%) 
0.06 
 
0.8  
(0.2 to 3.7) 
1.1  
(0.3 to 4.6) 
UED 
Present 
100% (23) 
 
74% (17) 
(65% to 83%) 
0.03 
 
96% (20) 
(92% to 100%) 
76% (16) 
(67% to 85%) 
0.1 
 
62% (13) 
(51% to 63%) 
0.02 
 
0.9  
(0.2 to 3.5) 
1.7  
(0.5 to 6.3) 
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Table 5: Demographics of followed-up participants and assessment scores at follow-up.  
 
 
Variable 
Trial 
baseline 
n = 48 
1-month 
post-therapy 
n=29 
Baseline to 1-month 
post-therapy  
n=29 
1-4 year 
FU 
n=16 
Baseline/1-month post-
therapy to 1-4 year FU, 
n=13 
 Mean (SD) Mean (SD) ES (95% CI) Mean (SD) ES (95% CI) 
Age (years) 11.7 (2.1)1 11.4 (2.1) - 11.5 (2.0)6 - 
IQ (BPVS) 87.0 (16.5) 88.1 (13.8) - 90.2 (13.8)6 - 
SDQ-ESS 7.3 (1.2) 5.2 (2.0) 1.2 (0.6 to 1.8)*** 5.4 (2.8) 
1.1 (-0.0 to 2.2)*/ 
-0.1 (-0.5 to 0.3), NS 
UE-frequency 8.1 (5.1) 3.3 (5.0) 0.8 (0.4 to 1.2)*** 4.4 (4.8) 
0.7 (0.1 to 1.3)*/ 
0.04 (-0.6 to 0.7), NS 
UE-D&I 10.9 (8.2) 3.5 (5.3) 1.0 (0.5 to 1.5)*** 6.2 (5.7) 
0.5 (-0.1 to 1.1), NS/ 
-0.4 (-1.2 to 0.4), NS 
UED-number 3.8 (2.1) 1.4 (2.1) 1.0 (0.5 to 1.5)*** 2.6 (2.3) 
0.5 (-0.0 to 1.0)*/ 
-0.4 (-1.0 to 0.2), NS 
UE-number 4.4 (2.2) 2.0 (2.4) 1.1 (0.6 to 1.6)*** 3.7 (2.4) 
0.3 (-0.2 to 0.8), NS/ 
-0.5 (-1.1 to 0.1), NS 
UED-severity 23.8 (16.0) 8.1 (13.1) 1.0 (0.5 to 1.5)*** 13.4 (12.8) 
0.6* (-0.0 to 1.2)/ 
-0.5 (-1.3 to 0.3), NS 
Depression 12.0 (6.0)2 9.0 (7.1)3 0.3 (-0.1 to 0.7), NS - - 
Anxiety 45.9 (17.5) 30.7 (18.3)3 0.6 (0.2 to 1.0)** - - 
SDQ-Total 20.7 (5.0) 16.2 (5.3) 0.6 (0.2 to 1.0)** 16.6 (8.0) 
0.3 (-0.4 to 1.0), NS/ 
0.2 (-0.2 to 0.6)), NS 
 
% (n) 
(95% CI) 
% (n) 
(95% CI) 
McNemar Test 
% (n) 
(95% CI) 
McNemar Test 
Gender (F:M) 
53%:47% 
(26:23)1 
52%:48% 
(15:14) 
- 
53%:47% 
(10:9)6 
- 
Ethnicity 
BME/non-BME 
46%:54% 
(22:26) 
45%:55% 
(13/16) 
- 
37%/63% 
(7:12)6 
- 
SCREEN+ve 100% (48) 
34% (10) 
(25% to 43%) 
p=0.002 
38% (6) 
(25% to 43%) 
p=0.008/NS 
SDQ-ESS 
Clinical range 
100% (48) 
48% (14) 
(39% to 57%) 
p<0.001 
38% (6) 
(26% to 50%) 
p=0.008, NS 
UE 
Present 
100% (48) 
69% (20) 
(60% to 78%) 
p=0.004 
88% (14) 
(80% to 96%) 
NS, NS 
UED 
Present 
98% (47) 
(96% to 100%) 
52% (15) 
(43% to 61%) 
p<0.001 
81% (13) 
(71% to 91%) 
NS, NS 
Family/ 
Parental MI 
73%/43% 
(36/21)1 
79%/45% 
(23/13) 
- 
84%/53% 
(16/10)6 
- 
Speech/motor 
delay/problem 
37% (13)4 21% (6)5 - 21% (4)7 - 
Key: FU: follow-up; SD: standard deviation; df: degrees of freedom; IQ: Intelligence Quotient; BPVS = British Picture 
Vocabulary Scale (Dunn et al., 1997). SDQ: Strengths and Difficulties Questionnaire (Goodman, 2001); ESS: Emotional 
Symptoms Scale; UE = unusual experience; UE-D&I: Distress and adverse impact associated with UE; UED = unusual 
experience with distress or adverse impact; BME: Black or minority ethnic; SCREEN+ve: scoring in the clinical range (SDQ-
ESS ≥6; UE-number ≥1); MI: Self-reported mental illness history;  1n=additional TAU participant (n=49); 2n=46; 3n=28; 
4n=35; 5n=17; 6n=19 (includes 3 non-treatment cases); 7n=15. ES: effect size, Cohen’s d, derived from pre-post change mean 
differences over the common SD; *p<0.05; **p<0.01; ***p<0.001 – significance levels derived from within group paired t-test 
of pre-post scores. 
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Appendix A: CONSORT checklist 
Section/Topic 
Item 
No Checklist item 
Reported 
on page 
No 
Title and abstract 
 1a Identification as a pilot or feasibility randomised trial in the title 1 
1b Structured summary of pilot trial design, methods, results, and conclusions (for specific guidance 
see CONSORT abstract extension for pilot trials) 
3 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale for future definitive trial, and reasons for 
randomised pilot trial 
5-6 
2b Specific objectives or research questions for pilot trial 6 
Methods 
Trial design 3a Description of pilot trial design (such as parallel, factorial) including allocation ratio 9-10 
3b Important changes to methods after pilot trial commencement (such as eligibility criteria), with 
reasons 
N/A 
Participants 4a Eligibility criteria for participants 6, 9-10 
4b Settings and locations where the data were collected 6 
 4c How participants were identified and consented 6, 10 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when 
they were actually administered 
11 
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Outcomes 6a Completely defined prespecified assessments or measurements to address each pilot trial objective 
specified in 2b, including how and when they were assessed 
9-10 
6b Any changes to pilot trial assessments or measurements after the pilot trial commenced, with 
reasons 
N/A 
 6c If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive 
trial 
9-10 
Sample size 7a Rationale for numbers in the pilot trial 9 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
Randomisation:    
Sequence  
generation 
8a Method used to generate the random allocation sequence 9 
8b Type of randomisation(s); details of any restriction (such as blocking and block size) 9 
Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered 
containers), describing any steps taken to conceal the sequence until interventions were assigned 
N/A 
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned 
participants to interventions 
9 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care 
providers, those assessing outcomes) and how 
N/A 
11b If relevant, description of the similarity of interventions 9-11 
Statistical 
methods 
12 Methods used to address each pilot trial objective whether qualitative or quantitative 12-14 
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Results 
Participant flow 
(a diagram is 
strongly 
recommended) 
13a For each group, the numbers of participants who were approached and/or assessed for eligibility, 
randomly assigned, received intended treatment, and were assessed for each objective 
14,33 
13b For each group, losses and exclusions after randomisation, together with reasons 14, 33 
Recruitment 14a Dates defining the periods of recruitment and follow-up 14 
14b Why the pilot trial ended or was stopped N/A 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 34 
Numbers 
analysed 
16 For each objective, number of participants (denominator) included in each analysis. If relevant, 
these numbers should be by randomised group 
14-20, 35-
37 
Outcomes and 
estimation 
17 For each objective, results including expressions of uncertainty (such as 95% confidence interval) 
for any 
estimates. If relevant, these results should be by randomised group 
14-20, 35-
37 
Ancillary 
analyses 
18 Results of any other analyses performed that could be used to inform the future definitive trial 14-20 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 16-17 
 19a If relevant, other important unintended consequences 16-17 
Discussion 
Limitations 20 Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility 20-23 
Generalisability 21 Generalisability (applicability) of pilot trial methods and findings to future definitive trial and other 
studies 
20-23 
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Interpretation 22 Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and 
harms, and 
considering other relevant evidence 
20-23 
 22a Implications for progression from pilot to future definitive trial, including any proposed amendments 20-23 
Other information 
 
Registration 23 Registration number for pilot trial and name of trial registry 5 
Protocol 24 Where the pilot trial protocol can be accessed, if available 10 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 24 
 26 Ethical approval or approval by research review committee, confirmed with reference number 10 
Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. 
BMJ. 2016;355. 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010, extension to randomised pilot and feasibility trials, Explanation and Elaboration for 
important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, 
non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this 
checklist, see www.consort-statement.org. 
 
 
